A Phase I study of intrathecal resiniferatoxin in patients with advanced cancer pain shows promising reductions in pain and opioid use, with durable effects and manageable side effects.
Researchers found that nearly 15% of commercially insured PrEP users had an alcohol use disorder diagnosis, yet fewer than 9% received FDA-approved treatment.
The new guidance is intended to “foster drug product development, ANDA submission and approval, and ultimately provide increased access to generic drugs."
The FDA has cleared the first blood-based test to aid in diagnosing Alzheimer’s disease, offering a less invasive alternative to positron emission tomography scans and cerebrospinal fluid testing for cognitively impaired patients.
2023 brought record-breaking heat waves in the United States, significantly impacting vulnerable groups. Analysis by the CDC revealed a substantial number of heat-related illness (HRI) emergency department visits, resulting in multiple public health alerts.